The estimated Net Worth of David Lamond is at least $2.13 million dollars as of 20 May 2022. Mr. Lamond owns over 66,500 units of Cortexyme Inc stock worth over $2,101,162 and over the last 6 years he sold CRTX stock worth over $0. In addition, he makes $33,750 as Independent Director at Cortexyme Inc.
David has made over 6 trades of the Cortexyme Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 66,500 units of CRTX stock worth $210,805 on 20 May 2022.
The largest trade he's ever made was buying 66,500 units of Cortexyme Inc stock on 20 May 2022 worth over $210,805. On average, David trades about 17,830 units every 46 days since 2019. As of 20 May 2022 he still owns at least 1,077,519 units of Cortexyme Inc stock.
You can see the complete history of Mr. Lamond stock trades at the bottom of the page.
David A. Lamond J.D. serves as Independent Director of the Company. Mr. Lamond has served as the president of En Pointe LLC, an investment firm, since 2016. He served as the President, Chief Executive Officer and Chief Investment Officer of Lamond Capital Partners LLC from 2011 to 2016. He also serves on the board of directors of Applied Molecular Transport, a biotechnology company. Lucira Health Inc, a molecular diagnostics company, Inquis Medical, a medical device company and Genelpis SAS, a biotech company. He previously served on the board of Arrinex, a medical device company until its acquisition by Stryker Corporation in February 2019. In addition, he serves on the board of directors of two non-profit organizations, Tipping Point Community and Ubuntu Pathways. Mr. Lamond holds a B.A. in History from Duke University and a J.D. from Duke Law School.
As the Independent Director of Cortexyme Inc, the total compensation of David Lamond at Cortexyme Inc is $33,750. There are 13 executives at Cortexyme Inc getting paid more, with Michael Detke having the highest compensation of $1,100,170.
David Lamond is 45, he's been the Independent Director of Cortexyme Inc since 2015. There are 18 older and no younger executives at Cortexyme Inc. The oldest executive at Cortexyme Inc is Una Ryan, 78, who is the Lead Independent Director.
David's mailing address filed with the SEC is C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi et Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: